Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 8/20 | 0.44 |
| ▸ | PPARA | Q07869 | 6/20 | 0.44 |
| ▸ | PPARD | Q03181 | 5/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 3/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096852 | 0.90 | ACLY (0.53) | ACLYPPARGPPARAPPARDPHGDH | |
| SCHEMBL28800057 | 0.85 | ACLY (0.43) | ACLYCA1CA2CA9PPARG | |
| SCHEMBL28800056 | 0.83 | ACLY (0.41) | ACLYCA1CA2CA9PPARG | |
| SCHEMBL12096711 | 0.81 | PPARG (0.52) | ACLYPPARGPPARAPPARDCCR2 | |
| SCHEMBL12096867 | 0.77 | PPARG (0.47) | ACLYCA1CA2CA9PPARG | |
| SCHEMBL12096680 | 0.76 | ACLY (0.52) | ACLYPPARGPPARAPPARDCCR2 | |
| SCHEMBL12096941 | 0.75 | PPARG (0.52) | ACLYPPARGPPARAPPARDPHGDH | |
| SCHEMBL17927565 | 0.75 | PPARG (0.48) | PPARGPPARAPPARD | |
| SCHEMBL12096836 | 0.74 | PPARG (0.43) | ACLYPPARGPPARAPPARDPHGDH | |
| SCHEMBL12096736 | 0.74 | ACLY (0.49) | ACLYPPARGPPARAPPARDPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | ACLY 3538/4885CA1 4719/4885CA2 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.